Kiadis B.V. and CiMaas B.V. formalize a collaboration on the production of Natural Killer cells for the treatment of cancer

november 5, 2019

Kiadis and CiMaas, Dutch developers and producers of cell therapy for cancer, have now signed an agreement to co-develop a fast and efficient production process to generate high numbers of Natural Killer Cells with strong capacity to kill tumor cells.

CiMaas (Maastricht, NL) also has a focus on the development of cell therapy against cancer. Its’ lead product – a cell vaccine against several types of cancer – will go into clinical phase studies in 2020.

Before the acquisition of Cytosen by Kiadis, CiMaas - in close collaboration with the University of Maastricht - had a long-standing collaboration with Cytosen on the development of NK cells.  

Wilfred Germeraad – CSO of CiMaas: CiMaas and Cytosen, recently acquired by Kiadis Pharma, have co-developed an efficient methodology for culturing and expanding NK cells over the last years, to large numbers required for treating cancer patients. CiMaas and Kiadis will now collaborate to develop an even more efficient methodology for culturing large numbers of NK cells from blood. Kiadis’ knowledge of process technology and scale up aims to decrease the time and cost needed for these therapies.

Mathieu Streefland – Director Process Development at Kiadis: the CiMaas team has extensive knowledge on NK cell culture and functional testing. Together with our expertise on process development of cell therapies, we hope that our collaboration with Cimaas will enhance our capabilities for a fast, reliable and cost-effective NK cell expansion process.

About CiMaas

CiMaas aims to develop cellular immunotherapy for specific groups of cancer patients. The company develops unique products based on cells and antibodies from the immune system. CiMaas BV is a spin-off of Maastricht University/Maastricht University Medical Centre+ (UM/Maastricht UMC+).

About Kiadis

Founded in 1997, Kiadis Pharma, is a fully integrated biopharmaceutical company committed to developing innovative therapies for patients with life threatening diseases. With headquarters in Amsterdam, the Netherlands, and offices in the US and across Europe, Kiadis Pharma is leveraging the natural strengths of humanity and our collective immune system to source the best cells for life. Kiadis Pharma is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at www.kiadis.com.

  overview news & events